Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure.

ABSTRACT:

Background

Sacubitril/valsartan (S/V) improves outcomes in patients with heart failure with reduced ejection fraction (HFrEF). Data about the immediate, short-, and intermediate-term hemodynamic effects of S/V are limited.

Methods

In this prospective observational study, 37 outpatients with chronic HFrEF were treated with S/V according to current guideline recommendations. Next to clinical, laboratory and echocardiographic parameters, haemodynamic variables were assessed non-invasively by use of inert gas rebreathing and bioimpedance cardiography at baseline and at 2-week, 3-month and 6-month follow-up. The course of variables throughout the study and the relationship between variables were analysed using fractional polynomials.

Results

S/V treatment resulted in short

SUBMITTER: Frohlich H 

PROVIDER: S-EPMC9493168 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature